150915-41-6 Usage
Uses
Used in Pharmaceutical Industry:
Perospirone is used as an antipsychotic agent for the treatment of schizophrenia and other psychoses. Its unique binding profile and high affinity for specific neurotransmitter receptors contribute to its lower propensity for causing extrapyramidal symptoms (EPS) and tardive schizophrenia, making it a promising alternative to classical antipsychotic therapies.
Used in Clinical Trials:
Perospirone is used as a subject in long-term clinical trials (lasting more than 6 months) to evaluate its efficacy in treating the positive, negative, and general symptoms of schizophrenia. These trials have demonstrated the effectiveness of perospirone at doses ranging from 12 mg to 96 mg t.i.d. compared to placebo.
Used in Anxiety Treatment:
Perospirone is used as an anxiolytic agent, as it has shown anxiolytic-like effects in animal models. This suggests that it may have potential applications in treating anxiety-related disorders in addition to its primary use in treating schizophrenia and other psychoses.
Brand Name:
Perospirone is marketed under the brand name Lullan.
Originator
Sumitomo Pharm. (Japan)
Check Digit Verification of cas no
The CAS Registry Mumber 150915-41-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,9,1 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 150915-41:
(8*1)+(7*5)+(6*0)+(5*9)+(4*1)+(3*5)+(2*4)+(1*1)=116
116 % 10 = 6
So 150915-41-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+
150915-41-6Relevant academic research and scientific papers
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
-
, (2008/06/13)
The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.
Succinimide derivatives. II. Synthesis and antipsychotic activity of N- [4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds
Ishizumi,Kojima,Antoku,Saji,Yoshigi
, p. 2139 - 2151 (2007/10/03)
Cyclic imides bearing ω-(4-benzisothiazol-3-yl-1-piperazinyl)alkyl moieties were synthesized and tested for antipsychotic activity. The in vitro binding affinities of these compounds were examined for dopamine 2 (D2) and serotonin 2 (5-HT2) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, N-[4-[4-(1,2- benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarboximide (SM-9018), was found to be more potent and more selective in vivo than tiospirone in its antipsychotic activity. SM-9018 (17) is currently undergoing clinical evaluation as a selective antipsychotic agent.
